Effects of a combined oral contraceptive containing oestradiol valerate/dienogest on hormone withdrawal-associated symptoms: Results from the multicentre, randomised, double-blind, active-controlled HARMONY II study

References

• Ahrendt HJ, Makalova D, Parke S, Mellinger U, Mansour D. 2009. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. Contraception 80:436–444.
   PubMed Web of Science ®Google Scholar
• Allais G, Castagnoli Gabellari I, De Lorenzo C, Mana O, Benedetto C. 2011. Oral contraceptives in migraine therapy. Neurological Sciences 32(Suppl 1):S135–S139.
   Google Scholar
• Allais G, Gabellari IC, Airola G, Borgogno P, Schiapparelli P, Benedetto C. 2009. Headache induced by the use of combined oral contraceptives. Neurological Sciences 30(Suppl 1):S15–S7.
   PubMedGoogle Scholar
• Bayer HealthCare Pharmaceuticals. 2008. First estradiol-based oral contraceptive Qlaira® cleared for market launch in Europe. Available at: www.investor.bayer.de/en/news/archive/investor-news-2008/investor-news/showNewsItem/1008/1235464620/14ac57ccfd (Accessed 5 July 2012).
   Google Scholar
• Bayer HealthCare Pharmaceuticals. 2010. US FDA approves Natazia™, a new oral contraceptive for the prevention of pregnancy. Available at: http://pharma.bayer.com/scripts/pages/en/news_room/news_room/news_room91.php (Accessed 5 July 2012).
   Google Scholar
• Endicott J, Nee J, Harrison W, Blumenthal R. 1993. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacology Bulletin 29:321–326.
   PubMed Web of Science ®Google Scholar
• European Agency for the Evaluation of Medicinal Products (EMEA) Committee for Proprietary Medicinal Products (CPMP). 2002. Note for guidance on clinical investigation of medicinal products for treatment of nociceptive pain. Available at: www.tga.gov.au/pdf/euguide/ewp061200 final.pdf (Accessed 5 July 2012).
   Google Scholar
• Headache Classification Subcommittee of the International Headache Society. 2004. The International Classification of Headache Disorders, 2nd edn. Cephalalgia 24(Suppl 1):9–160.
   Google Scholar
• Jensen JT, Parke S, Mellinger U, Serrani M, Mabey RG Jr. 2013. Hormone withdrawal-associated symptoms: Comparison of oestradiol valerate/dienogest versus ethinylestradiol/norgestimate. European Journal of Contraception and Reproductive Health Care: Epub ahead of print May 2.
   Google Scholar
• Klipping C, Duijkers I, Trummer D, Marr J. 2008. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception 78:16–25.
   PubMed Web of Science ®Google Scholar
• MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A. 2006. Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen. Neurology 67:2154–2158.
   PubMed Web of Science ®Google Scholar
• Martelletti P, Farinelli I, Coloprisco G, Patacchioli FR. 2007. Role of NSAIDs in the acute treatment of headache. Drug Development Research 68:276–281.
   Web of Science ®Google Scholar
• Rosenberg MJ, Waugh MS, Meehan TE. 1995. Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation. Contraception 51:283–288.
   PubMed Web of Science ®Google Scholar
• Rosenberg MJ, Waugh MS. 1998. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. American Journal of Obstetrics and Gynecology 179:577–582.
   PubMed Web of Science ®Google Scholar
• Silberstein SD. 2001. Headache and female hormones: what you need to know. Current Opinion in Neurology 14:323–333.
   PubMed Web of Science ®Google Scholar
• Spona J, Elstein M, Feichtinger W et al. 1996. Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception 54:71–77.
   PubMed Web of Science ®Google Scholar
• Sulak PJ, Cressman BE, Waldrop E, Holleman S, Kuehl TJ. 1997. Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms. Obstetrics and Gynecology 89: 179–183.
   PubMed Web of Science ®Google Scholar
• Sulak P, Willis S, Kuehl T, Coffee A, Clark J. 2007a. Headaches and oral contraceptives: impact of eliminating the standard 7-Day placebo interval. Headache 47:27–37.
   PubMed Web of Science ®Google Scholar
• Sulak PJ, Kaunitz AM, London AM, Moore AM, Nelson AL. 2007b. Extended regimen oral contraceptives – practical management. Journal of Family Practice 56:S1–S8.
   Google Scholar
• Sulak PJ, Scow RD, Preece C, Riggs MW, Kuehl TJ. 2000. Hormone withdrawal symptoms in oral contraceptive users. Obstetrics and Gynecology 95:261–266.
   PubMed Web of Science ®Google Scholar
• Zeun S, Lu M, Uddin A, Zeiler B, Morrison D, Blode H. 2009. Pharmacokinetics of an oral contraceptive containing oestradiol valerate and dienogest. European Journal of Contraception and Reproductive Health Care 14:221–232.
   PubMed Web of Science ®Google Scholar